PT  - JOURNAL ARTICLE
AU  - Motoki Nakamura
AU  - Kotaro Nagase
AU  - Maki Yoshimitsu
AU  - Tetsuya Magara
AU  - Yuka Nojiri
AU  - Hiroshi Kato
AU  - Tadahiro Kobayashi
AU  - Yukiko Teramoto
AU  - Masahito Yasuda
AU  - Hidefumi Wada
AU  - Toshiyuki Ozawa
AU  - Yukie Umemori
AU  - Dai Ogata
AU  - Akimichi Morita
TI  - Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma
AID  - 10.1136/jitc-2020-001679
DP  - 2020 Dec 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e001679
VI  - 8
IP  - 2
4099  - http://jitc.bmj.com/content/8/2/e001679.short
4100  - http://jitc.bmj.com/content/8/2/e001679.full
SO  - J Immunother Cancer2020 Dec 01; 8
AB  - Background Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer. Some cases have a good prognosis and spontaneous regression can occur. Reported prognostic markers, such as Merkel cell polyoma virus infection or programmed death ligand-1 (PD-L1) expression, remain insufficient for precisely estimating the vastly different patient outcomes. We performed RNA sequencing to evaluate the immune response and comprehensively estimate prognostic values of immunogenic factors in patients with MCC.Methods We collected 90 specimens from 71 patients and 53 blood serum samples from 21 patients with MCC at 10 facilities. The mRNA was extracted from formalin-fixed paraffin-embedded tissues. Next-generation sequencing, immunohistochemical staining and blood serum tests were performed.Results Next-generation sequencing results classified MCC samples into two types: the ‘immune active type’ was associated with better clinical outcomes than the ‘cell division type’. Expression of the glucose-6-phosphate dehydrogenase (G6PD) gene was highly significantly upregulated in the ‘cell division type’. Among 395 genes, G6PD expression correlated with the presence of lymph node or distant metastases during the disease course and significantly negatively correlated with PD-L1 expression. Immunohistochemical staining of G6PD also correlated with disease-specific survival and exhibited less heterogeneity compared with PD-L1 expression. G6PD activity could be measured by a blood serum test. The detection values significantly increased as the cancer stage progressed and significantly decreased after treatment.Conclusions G6PD expression was an immunohistochemically and serum-detectable prognostic marker that negatively correlated with immune activity and PD-L1 levels, and could be used to predict the immunotherapy response.